Patent application number | Description | Published |
20080252653 | CALIBRATING RGBW DISPLAYS - A method for calibrating a display device having four or more channels, including three main channels which include in their gamut a desired display white point, and one or more further channels, said display device also having one or more individual adjustment controls for each channel. The method uses a series of targets, which are each one or more activated display settings at which the luminance and chromaticity coordinates are measured and recorded. | 10-16-2008 |
20080252797 | METHOD FOR INPUT-SIGNAL TRANSFORMATION FOR RGBW DISPLAYS WITH VARIABLE W COLOR - A method for transforming three color-input signals (R, G, B) corresponding to three gamut-defining color primaries of a display to four color-output signals (R′, G′, B′, W) corresponding to the gamut-defining color primaries and one additional primary of the display, where the additional primary has color that varies with drive level, comprising: a) determining a relationship between drive level of the additional primary and intensities of the three gamut-defining primaries which together produce equivalent color over a range of drive levels for the additional primary; and b) employing the three color-input signals R, G, B and the relationship defined in a) to determine a value for W of the four color-output signals, and modification values to be applied to one or more of the R, G, B components of the three color-input signals to form the R′, G′, B′ values of the four color-output signals. | 10-16-2008 |
20090079753 | PREFERENTIAL TONE SCALE FOR ELECTRONIC DISPLAYS - A method of displaying on a display a visual reproduction of an original scene with a preferential tone mapping; said display having a selected display white point and a selected display black point separated by more than 3.5 decades of luminance; the method comprising the steps of capturing original scene parameters, performing a transformation on said captured scene parameters, and displaying a visual reproduction of the scene on the display from the transformed captured scene parameters; wherein said transformation, taken in conjunction with untransformed characteristics of the capturing and displaying steps, results in a reproduced tone mapping having: a. a dynamic range greater than 3.5 decades; b. a first derivative value of minus log reproduced luminance relative to log original scene luminance between −1.1 and −1.51 inclusive for a log scene luminance of −0.6, measured relative to a 100% diffuse reflector in the original scene; c. a first derivative value less than or equal to −1.9 and greater than −4.0 for a log scene luminance of −1.9; d. a first derivative value between −1.5 and −3.0 inclusive for a log scene luminance of −2.0; and e. a first derivative value at a log scene luminance of −2.5 greater than the first derivative value at a log scene luminance of −2.0. | 03-26-2009 |
20100073338 | INCREASING DYNAMIC RANGE OF DISPLAY OUTPUT - A method of controlling an RGBW electroluminescent display system that receives a three-component input image signal having triplets of intensity values in an image range and a highlight range includes transforming at least one of the triplets having an intensity value within the image range to a four-or-more-component drive signal to produce a luminance less than the sum of the corresponding luminance values of the red, green and blue light-emitting elements and transforming at least one of the intensity values within a triplet having an intensity value within the highlight range to a four-or-more-component drive signal to produce a luminance greater than the sum of the corresponding luminance values of the red, green, and blue light-emitting elements. | 03-25-2010 |
20100102283 | COLOR FILTER ELEMENT WITH IMPROVED COLORANT DISPERSION - A color filter having a filter layer comprising a fluorinated phthalocyanine pigment and at least one second pigment. In one embodiment, the second pigment has a maximum absorption at a wavelength from 400 to 500 nm to create a green color filter. | 04-29-2010 |
20110052801 | GREEN COLOR FILTER ELEMENT - A green color filter having a green filter layer comprising a bridged aluminum phthalocyanine pigment and a second pigment having its maximum absorption at a wavelength from 400 to 500 nm. | 03-03-2011 |
20110183066 | DISPLAY WITH RGB COLOR FILTER ELEMENT SETS - An electronic display containing a light source and a color filter set, the color filter set comprising: a green color filter having a green filter layer comprising a first pigment having its maximum absorption at a wavelength from 600 to 700 nm wherein at least 90 volume percent of the first pigment particles have a particle size less than 300 nm, and a second pigment having its maximum absorption at a wavelength from 400 to 500 nm wherein at least 90 volume percent of the second pigment particles have a particle size less than 300 nm, and wherein the green filter layer has a transmittance of 60% or more at a wavelength of 520 nm and of no more than 10% at a wavelength of 480 nm and of no more than 10% at a wavelength of 590 nm; a blue color filter having a blue filter layer; a red color filter having a red filter layer; and wherein the color gamut defined by the electronic display has a % NTSCx,y ratio greater than 88%. | 07-28-2011 |
20110299143 | COLOR TRANSFORM INSENSITIVE TO PROCESS VARIABILITY - A method for determining a blended color transform for use in producing printed colors on a color printer having at least four device color channels, comprising: forming first and second color transforms, wherein the first color transform produces printed colors that have a reduced sensitivity to color printer process variations in at least a first region of color space that includes a near-neutral color region, and wherein the second color transform produces printed colors that have a reduced image noise visibility in at least a second region of color space; defining a blending function which computes weighting values for the first and second color transforms as a function of input color values; and using a processor to determine the blended color transform by blending the first color transform and the second color transform, responsive to the blending function. | 12-08-2011 |
Patent application number | Description | Published |
20080260840 | Suspension formulations of insulinotropic peptides and uses thereof - A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described. | 10-23-2008 |
20090202608 | Devices, formulations, and methods for delivery of multiple beneficial agents - The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention. | 08-13-2009 |
20100092566 | Highly concentrated drug particles, formulations, suspensions and uses thereof - Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability. | 04-15-2010 |
20100185184 | Osmotic delivery systems and piston assemblies for use therein - An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation. The piston assembly typically comprises a body constructed and arranged for positioning in the lumen. The body is typically made of a polymeric material that is, for example, resistant to leaching in an organic solvent. In one embodiment, the body is a columnar body having a rim at a distal end thereof for engaging and sealing against a wall of the reservoir and the piston assembly further comprises a spring retained at the distal end of the columnar body for biasing the rim of the columnar body against the wall of the reservoir. | 07-22-2010 |
20110076317 | Rapid establishment and/or termination of substantial steady-state drug delivery - The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics. | 03-31-2011 |
20110166554 | Osmotic delivery systems and piston assemblies for use therein - An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation. The piston assembly typically comprises a body constructed and arranged for positioning in the lumen. The body is typically made of a polymeric material that is, for example, resistant to leaching in an organic solvent. In one embodiment, the body is a columnar body having a rim at a distal end thereof for engaging and sealing against a wall of the reservoir and the piston assembly further comprises a spring retained at the distal end of the columnar body for biasing the rim of the columnar body against the wall of the reservoir. | 07-07-2011 |
20120178687 | Suspension formulations of insulinotropic peptides and uses thereof - A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described. | 07-12-2012 |
20120289944 | HIGHLY CONCENTRATED DRUG PARTICLES, FORMULATIONS, SUSPENSIONS AND USES THEREOF - Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability. | 11-15-2012 |
20130030417 | Rapid Establishment and/or Termination of Substantial Steady-State Drug Delivery - The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics. | 01-31-2013 |
20130090287 | Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents - The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention. | 04-11-2013 |
20140378900 | Osmotic Delivery Systems and Piston Assemblies for Use Therein - An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation. The piston assembly typically comprises a body constructed and arranged for positioning in the lumen. The body is typically made of a polymeric material that is, for example, resistant to leaching in an organic solvent. In one embodiment, the body is a columnar body having a rim at a distal end thereof for engaging and sealing against a wall of the reservoir and the piston assembly further comprises a spring retained at the distal end of the columnar body for biasing the rim of the columnar body against the wall of the reservoir. | 12-25-2014 |